JP2017527274A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527274A5
JP2017527274A5 JP2017504103A JP2017504103A JP2017527274A5 JP 2017527274 A5 JP2017527274 A5 JP 2017527274A5 JP 2017504103 A JP2017504103 A JP 2017504103A JP 2017504103 A JP2017504103 A JP 2017504103A JP 2017527274 A5 JP2017527274 A5 JP 2017527274A5
Authority
JP
Japan
Prior art keywords
binding molecule
seq
sequence
bispecific binding
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017504103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527274A (ja
JP6871155B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/041989 external-priority patent/WO2016014942A1/en
Publication of JP2017527274A publication Critical patent/JP2017527274A/ja
Publication of JP2017527274A5 publication Critical patent/JP2017527274A5/ja
Application granted granted Critical
Publication of JP6871155B2 publication Critical patent/JP6871155B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017504103A 2014-07-25 2015-07-24 二重特異性her2及びcd3結合分子 Active JP6871155B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462029342P 2014-07-25 2014-07-25
US62/029,342 2014-07-25
PCT/US2015/041989 WO2016014942A1 (en) 2014-07-25 2015-07-24 Bispecific her2 and cd3 binding molecules

Publications (3)

Publication Number Publication Date
JP2017527274A JP2017527274A (ja) 2017-09-21
JP2017527274A5 true JP2017527274A5 (enExample) 2018-10-18
JP6871155B2 JP6871155B2 (ja) 2021-05-12

Family

ID=53836217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017504103A Active JP6871155B2 (ja) 2014-07-25 2015-07-24 二重特異性her2及びcd3結合分子

Country Status (15)

Country Link
US (2) US10519248B2 (enExample)
EP (1) EP3172236B1 (enExample)
JP (1) JP6871155B2 (enExample)
KR (1) KR102638104B1 (enExample)
CN (1) CN107124884B (enExample)
AU (1) AU2015292374B2 (enExample)
BR (1) BR112017001513A2 (enExample)
CA (1) CA2956014C (enExample)
ES (1) ES2832704T3 (enExample)
IL (1) IL250249B (enExample)
MX (1) MX386342B (enExample)
RU (1) RU2017105849A (enExample)
SG (1) SG11201700506TA (enExample)
WO (1) WO2016014942A1 (enExample)
ZA (1) ZA201701341B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3736292B1 (en) 2013-12-17 2024-05-08 Genentech, Inc. Anti-cd3 antibodies and methods of use
MX386342B (es) 2014-07-25 2025-03-18 Memorial Sloan Kettering Cancer Center Móleculas de unión a her2 y cd3 biespecíficas.
US11820832B2 (en) 2014-07-25 2023-11-21 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
EP3574012A1 (en) * 2017-01-27 2019-12-04 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
US11046768B2 (en) * 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
JP2020517591A (ja) * 2017-04-24 2020-06-18 メモリアル スローン ケタリング キャンサー センター 抗cd33抗体剤
CN107854490A (zh) * 2017-09-26 2018-03-30 首都医科大学附属北京世纪坛医院 一种经修饰的t细胞及其应用
SG11202007390YA (en) 2018-02-08 2020-08-28 Genentech Inc Bispecific antigen-binding molecules and methods of use
EP3765523A1 (en) * 2018-03-12 2021-01-20 Memorial Sloan Kettering Cancer Center Bispecific binding agents and uses thereof
US20210008113A1 (en) * 2018-03-27 2021-01-14 Systimmune, Inc. Methods of making and using guidance and navigation control proteins
CN110357960A (zh) * 2018-04-10 2019-10-22 广州爱思迈生物医药科技有限公司 抗体及抗体改造方法
JP7418346B2 (ja) * 2018-04-13 2024-01-19 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 4-1BBLを含むHer2標的化抗原結合分子
MX2020013606A (es) * 2018-06-14 2021-05-27 Bioatla Inc Constructos de anticuerpos multiespecificos.
CA3118397A1 (en) * 2018-11-01 2020-05-07 Shandong Newtime Pharmaceutical Co., Ltd. Bispecific antibody targeting cd3 and bcma, and uses thereof
CN111196856A (zh) * 2018-11-19 2020-05-26 三生国健药业(上海)股份有限公司 抗her2/pd1双特异性抗体
US20220098329A1 (en) * 2018-11-30 2022-03-31 Memorial Sloan Kettering Cancer Center Heterodimeric tetravalency and specificity antibody compositions and uses thereof
EP3894601A4 (en) * 2018-12-11 2023-01-11 The Translational Genomics Research Institute IDENTIFICATION OF HER2 MUTATIONS IN LUNG CANCER AND METHODS OF TREATMENT
EP3927749A4 (en) * 2019-02-22 2022-10-26 Memorial Sloan Kettering Cancer Center CD33 ANTIBODIES AND METHODS OF USE FOR THE TREATMENT OF CANCER
AU2020270888A1 (en) * 2019-04-08 2021-11-04 Memorial Sloan Kettering Cancer Center CD19 antibodies and methods of using the same
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
CN113874399B (zh) * 2019-05-23 2025-07-11 维洛斯生物股份有限公司 抗ror1/抗cd3双特异性结合分子
US20220251192A1 (en) * 2019-06-26 2022-08-11 Memorial Sloan Kettering Cancer Center Anti-cd33 antibodies for treating cancer
EP4072584B1 (en) 2019-12-13 2026-01-28 Genentech, Inc. Anti-ly6g6d antibodies and methods of use
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
AU2021315882A1 (en) * 2020-07-28 2023-03-02 Memorial Sloan Kettering Cancer Center Compositions including ex vivo armed T cells with multi-specific antibodies and uses thereof
WO2022081443A2 (en) * 2020-10-12 2022-04-21 Memorial Sloan Kettering Cancer Center Anti-psma antibodies and uses thereof
CA3196076A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
US12516118B2 (en) 2020-11-04 2026-01-06 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies and anti-CD79b antibody drug conjugates
MX2023005132A (es) 2020-11-04 2023-05-25 Genentech Inc Dosificacion para el tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3.
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス,インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
AU2022273541A1 (en) 2021-05-14 2023-11-30 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
EP4380638A4 (en) * 2021-08-04 2025-06-25 Abpro Corporation ANTI-HER2 ANTIBODIES AND THEIR USES
AU2022373303A1 (en) * 2021-10-20 2024-05-09 Memorial Hospital For Cancer And Allied Diseases Anti-tshr multi-specific antibodies and uses thereof
KR102803655B1 (ko) 2021-12-29 2025-05-08 건국대학교 글로컬산학협력단 개과 동물의 her1 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
KR102857671B1 (ko) 2021-12-29 2025-09-10 건국대학교 글로컬산학협력단 개과 동물의 her2 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
CA3247048A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE
CN120813831A (zh) * 2023-02-04 2025-10-17 伊玛吉恩生物系统公司 在磁共振成像中使用氧化铁纳米颗粒评估淋巴结疾病的方法
WO2025076473A1 (en) * 2023-10-06 2025-04-10 Fred Hutchinson Cancer Center Proteins bispecific to cd3 and nkg2dl and associated uses thereof
WO2025085781A1 (en) 2023-10-19 2025-04-24 Genentech, Inc. Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US7728114B2 (en) 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
EP3461842A1 (en) 2007-04-03 2019-04-03 Amgen Research (Munich) GmbH Cross-species-specific binding domain
US8648176B2 (en) 2009-02-27 2014-02-11 Massachusetts Institute Of Technology Engineered proteins with high affinity for DOTA chelates
CN107253992B (zh) 2010-05-27 2022-03-11 根马布股份公司 针对her2的单克隆抗体
JP6029581B2 (ja) 2010-06-19 2016-11-24 メモリアル スローン−ケタリング キャンサー センター 抗gd2抗体
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
CN103648530B (zh) * 2011-05-08 2017-02-08 乐高化学生物科学股份有限公司 蛋白质‑活性剂缀合物及其制备方法
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
JP6020581B2 (ja) * 2011-11-02 2016-11-02 味の素株式会社 タンパク質の分泌生産法
WO2013188693A1 (en) * 2012-06-15 2013-12-19 Imaginab, Inc. Antigen binding constructs to cd3
EP2922874A4 (en) * 2012-11-21 2016-10-19 Wuhan Yzy Biopharma Co Ltd BISPECIFIC ANTIBODIES
RU2727836C2 (ru) * 2013-07-25 2020-07-24 Сайтомкс Терапьютикс, Инк. Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения
LT3083686T (lt) 2013-12-17 2020-01-10 F. Hoffmann-La Roche Ag Vėžinių ligų gydymo būdai naudojant pd-1 ašies rišimosi antagonistus ir taksanus
MX386342B (es) 2014-07-25 2025-03-18 Memorial Sloan Kettering Cancer Center Móleculas de unión a her2 y cd3 biespecíficas.
AU2016219534B2 (en) 2015-02-09 2021-07-01 Massachusetts Institute Of Technology Multi-specific antibodies with affinity for human A33 antigen and dota metal complex and uses thereof
US11046768B2 (en) 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
EP3574012A1 (en) 2017-01-27 2019-12-04 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules

Similar Documents

Publication Publication Date Title
JP2017527274A5 (enExample)
RU2017105849A (ru) Биспецифические молекулы, связывающие her2 и cd3
Ma et al. Bispecific antibodies: from research to clinical application
JP2020063262A5 (enExample)
Marvin et al. Recombinant approaches to IgG‐like bispecific antibodies
JP2017520575A5 (enExample)
JP2019524693A5 (enExample)
JP2013527761A5 (enExample)
FI3749346T3 (fi) Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
JP2020533311A5 (ja) NKG2D、CD16およびNectin4に結合するタンパク質
JP2017504578A5 (enExample)
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
CA2798390A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
JP2020501531A5 (enExample)
JP2018503380A5 (enExample)
JP2018507188A5 (enExample)
RU2021110369A (ru) Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
WO2013044215A4 (en) Vegf/dll4 binding agents and uses thereof
RU2016151645A (ru) Биспецифические гетеродимерные диантитела и их применение
RU2022102446A (ru) Биспецифические связывающие белки и пути их применения
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
JP2019500011A5 (enExample)
IL295295A (en) Antibodies targeting fc receptor-like 5 and methods of use
WO2018119118A4 (en) Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof
JP2012519492A5 (enExample)